<!DOCTYPE html>
<html lang="en">
  
<!-- Mirrored from www.allindianpatents.com/patents/263856-process-for-producing-and-purifying-factor-viii-and-its-derivatives by HTTrack Website Copier/3.x [XR&CO'2014], Thu, 04 Apr 2024 22:41:35 GMT -->
<!-- Added by HTTrack --><meta http-equiv="content-type" content="text/html;charset=utf-8" /><!-- /Added by HTTrack -->
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=Edge,chrome=1">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Indian Patents. 263856:“PROCESS FOR PRODUCING AND PURIFYING FACTOR VIII AND ITS DERIVATIVES”</title>
    <meta content="authenticity_token" name="csrf-param" />
<meta content="cYcP52B8zyTWKbLwby2YPh9z/gvY/RLjWOwY4YXkiXg=" name="csrf-token" />

    <!-- Le HTML5 shim, for IE6-8 support of HTML elements -->
    <!--[if lt IE 9]>
      <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.6.1/html5shiv.js" type="text/javascript"></script>
    <![endif]-->

    <link href="../assets/application-e80cf34975c5b1730c80b2f7170e7d26.css" media="all" rel="stylesheet" type="text/css" />

  </head>
  <body>

    <div class="navbar navbar-fluid-top">
      <div class="navbar-inner">
        <div class="container-fluid">
          <a class="btn btn-navbar" data-target=".nav-collapse" data-toggle="collapse">
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
            <span class="icon-bar"></span>
          </a>
          <a class="brand" href="../index.html">Indian Patents</a>
          <div class="container-fluid nav-collapse">
            <ul class="nav">
              <li><a href="../recently-granted.html">Recently Granted Patents</a></li>
              <li><a href="../recently-published.html">Recently Published Patents</a></li>
            </ul>
            <form id="gform" class="navbar-search pull-right" action="https://www.google.com/search" method="get" target="_blank" onsubmit="document.getElementById('gform').q.value='site:http://www.allindianpatents.com '+document.getElementById('gform').q.value">
                <input type="text" name="q" id="q" class="search-query" placeholder="Search" onclick="this.value=''" autocomplete="off">
            </form>
          </div><!--/.nav-collapse -->
        </div>
      </div>
    </div>

    <div class="container-fluid">
      <div class="row-fluid">
        <div class="span12">

          <style>
          .allindianpatents-top { width: 320px; height: 50px; }
          @media(min-width: 500px) { .allindianpatents-top { width: 468px; height: 60px; } }
          @media(min-width: 800px) { .allindianpatents-top { width: 728px; height: 90px; } }
          </style>
          <center>
          </center>
          
          <div class="row-fluid">
	<div class="span8">

		<table class="table">
			<tr>
				<th>Title of Invention</th>
				<td><h1 style="font-size:large;">“PROCESS FOR PRODUCING AND PURIFYING FACTOR VIII AND ITS DERIVATIVES”</h1></td>
			</tr>
			<tr>
				<th>Abstract</th>
				<td>Disclosed is a method for producing proteins having factor VIII procoagulant activity in serum-free medium by in vitro culturing of mammalian cells, wherein the serum-free medium contains an inhibitor against the protease released from cultured cells. In accordance with this invention, the inhibitor can protect the cleavage of a target protein during cultivation and increase homogeneity of a target molecule, wherein the inhibitor can be a dextran sulfate. This invention also relates to a method of purifying target molecules from the culture medium containing both a target molecule and selected inhibitors by affinity chromatography.</td>
			</tr>
		</table>

					<style>
					.allindianpatents-post-abstract { width: 320px; height: 50px; }
					@media(min-width: 880px) { .allindianpatents-post-abstract { width: 468px; height: 60px; } }
					@media(min-width: 1267px) { .allindianpatents-post-abstract { width: 728px; height: 90px; } }
					</style>
					<center>
					<script async src="https://pagead2.googlesyndication.com/pagead/js/adsbygoogle.js"></script>
					<!-- AllIndianPatents-post-abstract -->
					<ins class="adsbygoogle allindianpatents-post-abstract"
					     style="display:inline-block"
					     data-ad-client="ca-pub-7914358224572760"
					     data-ad-slot="9152759240"></ins>
					<script>
					(adsbygoogle = window.adsbygoogle || []).push({});
					</script>					
					</center>

		<table class="table">
			<tr>
				<th>Full Text</th>
				<td>Background Art<br><br>
Factor VIII is a plasma glycoprotein involved in blood coagulation.<br><br>
Deficiency or abnormality in its function results in severe hereditary disease called<br><br>
hemophilia A (Eaton, D. et al., 1986, Biochemistry 25: 505-512; Toole, J. J. et al, 1984,<br><br>
Nature 312: 342-347; Vehar, G. A. et al., 1984, Nature 312: 337-342). Up to now, the<br><br>
only treatment for hemophilia A has been intravenous administration of factor VIII<br><br>
prepared from human blood or a recombinant source. Due to the safety reason,<br><br>
recombinant factor VIII has been preferred to plasma derived factor VIII. However,<br><br>
since expression level of factor VIII is 2-3 order magnitudes lower than other<br><br>
molecules in the same expression system (Lynch C. M., 1993, Human Gene Therapy<br><br>
4: 259-272), recombinant factor VIII production has not met its demand.<br><br>
Several attempts have achieved an improved expression of factor VIII by<br><br>
removing B-domain which has been known not to have any function in the cofactor<br><br>
activity of factor VIII (Eaton et al., 1986, Biochemistry 25:8343-8347; Burke, R. L. et al.,<br><br>
1986, J. Biol. Chem., 261: 12574-12578; Toole, J. J. et al., 1986, Proc. Natl. Acad. Sci.<br><br>
USA, 83: 5939-5942; Fay et al., 1986, Biochem. Biophys. Acta, 871:268-278). U. S. Pat.<br><br>
No. 5,661,008 and WO-A-91/ 09122 described B-domain deleted versions of factor<br><br>
VIII, which is similar to the shortest form of plasma factor VIII. U. S. Pat. No. <br><br>
5,112,950 and U. S. Pat. No. 7,041,635 disclosed the single chain forms of B-domain<br><br>
deleted factor VIII molecules.<br><br>
As a choice for the mammalian cell expression, Chinese Hamster Ovary<br><br>
(CHO) cell expression system has been used in producing many therapeutic proteins<br><br>
including factor VIII (Chu, L et al., 2001, Curr. Opin. Biotehnol., 12: 180-187). The<br><br>
characteristics of CHO cell line are elucidated. It can grow either in anchorage<br><br>
dependent manner or in suspension manner, adapt to either serum-containing<br><br>
medium or serum-free medium, and especially support post-translational<br><br>
modifications of proteins nearly identical to the human glycosylation patterns<br><br>
(Brooks S.A., 2004, MoI. Biotechnol., 28: 241-255; Jenkins, N., et al., 1996, Nat.<br><br>
Biotechnol., 14: 975-981; Chen, Z., et al., 2000, Biotechnol. Lett., 22: 837-941; MoIs, J.,<br><br>
et al., 2005, 41: 83-91). CHO cell lines producing therapeutic proteins have been<br><br>
usually cultured in the animal-derived protein free medium for the purpose of<br><br>
addressing safety concerns about transmission of animal derived virus or prion and<br><br>
for the purpose of easier purification. (Chu, L., et al., 2001, Curr. Opin. Biotehnol., 12:<br><br>
180-187). However, removal of serum from the cultivating media also deprives the<br><br>
naturally contained protease inhibitors in a serum supplement and makes it difficult<br><br>
to maintain the viability of the cells during the production processes (MoIs, ]., et al.,<br><br>
2005, 41: 83-91; Sandberg, H., et al., 2006, Biotechnol Bioeng., 95: 961-971).<br><br>
Reduced viability and stressful conditions seem to increase the production of<br><br>
secreted or released proteases from dead cells which can attack the therapeutic <br><br>
proteins and cause heterogeneity. Heterogeneity caused by internal cleavages of<br><br>
therapeutic protein might be the major problem because cleaved proteins can be<br><br>
inactive and make it difficult to maintain "lot to lot" consistency during the<br><br>
production and purification processes. Therefore, it is important to maintain a<br><br>
relatively low level of protease or to prevent protease activity during production.<br><br>
A few successful efforts to prevent this proteolysis caused by released<br><br>
proteases from CHO cell line during culture have been reported, even though<br><br>
universal inhibitor(s) which could apply to all therapeutic proteins produced in<br><br>
CHO cell line has not yet been found. Satoh M et al. reported the presence of cystein<br><br>
and serine proteases released from CHO cell. Chotteau et al. (Chotteau, V., et al.,<br><br>
2001, in Animal cell technology: from target to market, Kluwer Academic publishers, pp.<br><br>
287-292) found that an unidentified, extracellular metal-dependent protease from<br><br>
CHO cell culture medium was responsible for the proteolysis of truncated factor VIIL<br><br>
In WO- A- 90/ 02175, it is disclosed that some serine or cysteine proteases from CHO<br><br>
cell culture can be blocked by the inhibitor peptides, which increase factor VIII<br><br>
productivity. EP A 0 306 968 discloses addition of aprotinin to culture medium<br><br>
increased expression of factor VIII in CHO cell medium by three times.<br><br>
In U. S. Pat. No. 5,851,800, inventors claimed the inhibitors of<br><br>
metalloproteases and chymotrypsins could reduce detrimental effect on factor VIII<br><br>
production in cell culture. Sandberg H. et al. characterized two types of proteolytic<br><br>
activities released by CHO cells in a cell culture. One was originated from <br><br>
metalloproteinases, and the other from serine protease. Only metalloproteinases was<br><br>
found to have a strongly negative effect on the factor VIII activity. However, even<br><br>
though inhibitor of metalloproteases such as EDTA and 1,10 o-phenantroline could<br><br>
block the factor VIII cleavage as described by Sandberg H. et al., these inhibitors<br><br>
cannot be directly added into the CHO cell culture medium due to its toxic effect on<br><br>
cells, judged from our experiments.<br><br>
AU the above-mentioned protease inhibitors and commercially available<br><br>
protease cocktail which contain inhibitors against serine, cystein, aspartic and<br><br>
aminopeptidases such as aprotinin, bestatin, leupeptin, E-64 and pepstatin A have<br><br>
been applied to our single chain factor VIII derivative (described in U. S. Pat. No.<br><br>
7,041,635) culture, but we found that none of them were effective in protecting our<br><br>
factor VIII derivative from cleavage by released protease (s) from CHO cell culture<br><br>
during the culture.<br><br>
U. S. Pat. No. 6,300,100 discloses sulfated polysaccharide such as heparin<br><br>
protected an intact Tissue Factor Pathway Inhibitor (TFPI) from cleavage by<br><br>
proteases present in the culture medium. In addition, U. S. Pat. No. 5,112,950<br><br>
discloses sulfated dextran to substitute the stabilizing effect of Von Willebrand factor<br><br>
on factor VIII in serum free media. However, to our knowledge, there has been no<br><br>
report on the inhibitory effect of dextran sulfate against proteases in connection with<br><br>
factor VIII molecules.<br><br>
The present invention aims to demonstrate the protective effect of dextran <br><br>
sulfate on the cleavage of Factor VIII or its derivatives from proteases produced<br><br>
during CHO cell culture.<br><br>
Advantageous Effects<br><br>
In one aspect of this invention, there is provided a process for the production<br><br>
of Factor VIII or its derivatives in a mammalian host cell line adapted to serum-free<br><br>
media which is supplemented with dextran sulfate. Addition of dextran sulfate in<br><br>
culture media effectively reduced or blocked factor Vlll-cleaving activities of (a)<br><br>
certain protease(s) originated from CHO cell culture media and concurrently<br><br>
increased homogeneity of the produced factor VIII molecules. In another aspect of<br><br>
this invention, there is provided an efficient method for purifying factor VIII<br><br>
molecules from dextran sulfate-containing media using monoclonal antibody-based<br><br>
purification steps.<br><br>
This invention relates to an effective inhibitor which can protect our single<br><br>
chain factor VIII derivatives described in U. S. Pat. NO. 7,041,635 from cleavage by<br><br>
protease(s) released during a mammalian host cell cultivation and to increase the<br><br>
homogeneity of the produced factor VIII derivative. Also this invention relates to a<br><br>
method of purifying the factor VIII without being affected by addition of the<br><br>
protease inhibitor.<br><br>
The mammalian host cell may be any animal cell which can express<br><br>
recombinant factor VIII7 and is preferably an animal cell where a desired <br><br>
transformed cell can be easily separated, for example, a Chinese hamster ovary<br><br>
(CHO) cell, BHK cell, or COS cell, and more preferably a CHO cell.<br><br>
In the previous patent U. S. Pat. No. 6,300,100, there was a description about<br><br>
the protective effects of sulfated polysaccharides on a target protein against certain<br><br>
proteases, in which a target protein was Tissue Factor Pathway Inhibitor (TFPI).<br><br>
Therefore, we tested whether those sulfated polysaccharides could protect our target<br><br>
molecule-factor VIII. This invention showed that only dextran sulfate possesses a<br><br>
very strong protective effect on factor VIII cleavage when added to culture medium<br><br>
during cultivation process.<br><br>
Dextran sulfate can be obtained from bacterial fermentation or chemical<br><br>
synthesis. The molecular weights of dextran sulfate can vary from 20 to 5,000 kDa in<br><br>
molecular weight, and is preferably 50 to 2,000 kDa.<br><br>
Sulfur content of dextran sulfate can also vary depending on its source<br><br>
material. Regardless of the sulfur content of dextran sulfate, it can be employed to<br><br>
this invention only if the dextran sulfate can protect factor VIII from cleavage by<br><br>
?rotease(s) released from a cell cultivation process. The sulfur content of dextran<br><br>
sulfate is preferably in the range of 5 to 20 wt% of sulfated saccharide, more<br><br>
preferably more than 17 wt%,<br><br>
Depending on the expression level of factor VIII and its host cell line, the<br><br>
amount of dextran sulfate added to a growing media can be adjusted and not limited<br><br>
to those showed in preferred embodiments of this invention. <br><br>
In one preferred embodiment of this invention, factor VIII molecule is one<br><br>
of the factor VIII derivatives, named dBN(64-53)(hereafter called 12GdBN)7 which is<br><br>
disclosed in U. S. PAT. NO. 7,041,635. This factor VIII derivative has internal<br><br>
deletion in part of B-domain and N-terminal part of A3 and was designed to have a<br><br>
new N-glycosylation recognition sequence in its fusion site. As the method described<br><br>
in example 6 in U. S. PAT. NO. 7,041,635, a CHO cell line stably expressing the<br><br>
12GdBN was prepared and adapted to commercially available serum-free media.<br><br>
Hereinafter this clone is designated as "#39 clone" and all cells mentioned in<br><br>
examples are referred to this CHO cell line (#39).<br><br>
This invention also relates to a process for purifying factor VIII or derivatives<br><br>
expressed in mammalian host cell line from culture media supplemented with<br><br>
dextran sulfate using an affinity chromatography. The affinity chromatography<br><br>
includes affinity column which contains affinity molecules coupled to solid support<br><br>
such as agarose or sepharose. The affinity molecules can be anti-factor VIII<br><br>
antibodies which can be monoclonal or polyclonal and can be peptides with high<br><br>
affinity to factor VIII.<br><br>
Description of Drawings<br><br>
Figure 1 shows the comparative effects of different sulfated polysaccharides<br><br>
on protecting the cleavage of intact factor VIII.<br><br>
Figure 2 shows the effects of the molecular weight and concentration of <br><br>
dextran sulfate on the fragmentation of a B-domain deleted factor VIII, 12GdBN.<br><br>
Figure 3 shows the effects of sulfate, dextran, and dextran sulfate on the<br><br>
fragmentation of 12GdBN.<br><br>
Figure 4 shows the effect of dextran sulfate on the fragmentation of 12GdBN<br><br>
in perfusion culture in accordance with an embodiment of the present invention.<br><br>
Figure 5 shows a Coomassie Brilliant blue R250-statined SDS-PAGE gel of<br><br>
the elution fractions from an immunoaffinity chromatography in accordance with an<br><br>
embodiment of the present invention.<br><br>
Best Mode<br><br>
This invention is further illustrated with reference to the following Examples,<br><br>
but can be applied to other factor VIII molecules and other cell lines as it will be<br><br>
understood by the skilled person in the art. Therefore, the following examples<br><br>
should not be construed as limiting the scope of this invention.<br><br>
Heparin, Low molecular weight of heparins (~3 kDa and 4~6 kDa),<br><br>
Dermatan sulfate, dextran (500 kDa), sodium sulfate, dextran sulfate (500 kDa, 10<br><br>
kDa, 8 kDa) were purchased from Sigma. Dextrans were derived from Leuconostoc<br><br>
mesenteroides, strain B 512. Different molecular weights of dextran sulfate were<br><br>
produced by limited hydrolysis and fractionation. Sulfate groups were added by<br><br>
esterification with sulfuric acid under mild conditions. This dextran sulfate<br><br>
contained approximately 17 % of sulfur, (http://www.sigmaaldrich.com/sigma- <br><br>
aldrich/ product_inf ormation_sheet/ d6001pis.pdf)<br><br>
Plating #39 CHO cell line<br><br>
The above-described #39 clone, which is harboring DNA fragment encoding<br><br>
12GdBN/ was cultured in serum free media (ProCHOd media purchased from<br><br>
Cambrex). At two passages of subculture after thawing, 4 x 105 cells were seeded in<br><br>
each well of a 6-well plate.<br><br>
Western blot assay<br><br>
The culture medium containing expressed factor VIII was subjected to 7.5%<br><br>
SDS-PAGE gel and blotted to PVDF membrane. Blotted membrane was probed with<br><br>
an A2 domain-specific antibody called #26-1 which was generated by the inventors<br><br>
of this invention. Secondary mouse IgG coupled with horse-radish peroxidase was<br><br>
used to visualize the factor Vlll-anti factor VIII antibody complex on the blot.<br><br>
Example 1<br><br>
Comparison of protective effect of various sulfated polysaccharides on<br><br>
fragmentation of 12GdBN<br><br>
High molecular weight of dextran sulfate (about 500 kDa), heparin, two<br><br>
kinds of low molecular weight heparin (~3 kDa and 4~6 kDa), and dermartan sulfate<br><br>
were purchased from Sigma Co., Ltd. and resuspended in water and filter sterilized. <br><br>
Cells were plated as mentioned above. Twenty-four hours after seeding, the medium<br><br>
was replaced with a fresh one and five kinds of sulfated polysaccharides were added<br><br>
in each well at a final concentration of 25 mg/L, 50mg/L, 100mg/L, or 200mg/L,<br><br>
respectively. After 48 hours incubation, culture supernatants were collected and<br><br>
analyzed through Western blot assay. As shown in figure 1, there was little<br><br>
protection effect of three kinds of heparin which were effectively protecting TFPI<br><br>
described in other patents. However, dextran sulfate can provide efficient protection<br><br>
of cleavage and in a concentration-dependent manner. More than 92% of Factor VIII<br><br>
in the culture supernatant (lane 2 in figure 1-(D)) remained intact compared to the<br><br>
factor VIIIs in a culture medium with no additives (41%; lanel in figure 1-(D)) and<br><br>
the factor VIIIs in a culture medium with heparins or dermatan sulfate (52%~67%;<br><br>
lane 3~6 in figure 1-(D)). This shows that not all sulfated polysaccharides can protect<br><br>
all the target proteins and the protective effect of a certain sulfated polysaccharide is<br><br>
very specific to a target protein.<br><br>
Example 2<br><br>
Effect of molecular weight of Dextran sulfate on cleavage of 12GdBN<br><br>
If dextran sulfate with a lower molecular weight can be applied to protect the<br><br>
cleavage, a lower molecular weight of dextran sulfate may be easily separated from<br><br>
factor VIII more based on its difference in size. So, to see if lower molecular weight <br><br>
of dextran sulfate can protect the cleavage of expressed 12GdBN during cell<br><br>
cultivation, 8 kDa, 10 kDa and 500 kDa dextran sulfate, which have the same content<br><br>
of sulfur and originated from the same source, were added to the medium at varying<br><br>
concentrations of 100 mg/L, 200 mg/L, 400 mg/L and 1000 mg/L. At 72 hours after<br><br>
addition of dextran sulfate, culture medium was harvested and analyzed by Western<br><br>
blotting assay. As shown in figure 2, although an increasing amount of dextran<br><br>
sulfate with low molecular weight (lane 1 to lane 8 in figure 2) was added into the<br><br>
cell culture medium, there was not observed any efficient protective effect on<br><br>
12GdBN cleavage. Only 500 kDa dextran sulfate (lane 9 to lane 12) was shown to<br><br>
protect the fragmentation of single chain 12GdBN.<br><br>
Example 3<br><br>
Only sulfated dextran can protect the cleavage.<br><br>
To- see if a separate functional group of dextran sulfate has the inhibitory<br><br>
effect of cleavage, equimolar amounts of dextran (500 kDa), sodium sulfate, and<br><br>
dextran sulfate (500 kDa) were added in the culture medium. Cells were seeded as<br><br>
described in experiments. At 24 hours after seeding, several concentrations ranging<br><br>
from 250 mg/L to 1000 mg/L of dextran sulfate (500 kDa) and dextran (500 kDa) or<br><br>
several concentrations ranging from 71 g/L to 384 g/L of sodium sulfate were<br><br>
added to the medium. At 48 hours after addition, medium was collected from each<br><br>
Il <br><br>
well and analyzed by Western blot assay. As shown in figure 3, only 500 kDa<br><br>
dextran sulfate (lane 5 to lane 7) showed protective effect on cleavage of 12GdBN as<br><br>
depicted in figure 3. Neither dextran only (lane 2 to lane 4) nor sodium sulfate (lane<br><br>
8 to lane 10) was shown to inhibit the protease activities of released protease(s)<br><br>
during CHO cultivation. Fragmentation pattern of culture medium with either<br><br>
dextran or sodium sulfate only was similar to that of the culture medium with no<br><br>
additives (control, lane 1).<br><br>
Example 4<br><br>
Application of dextran sulfate to suspension culture<br><br>
Dextran sulfate (500 kDa) was applied to a perfusion culture system. One<br><br>
vial of cell was thawed and expanded in T75 flask and further expanded in T125<br><br>
flask. Cells in T125 flask were transferred into 250 ml, 1 L and 3 L spinner flasks<br><br>
serially and maintained as suspension culture on a magnetic stirrer plate at 37°C in<br><br>
5% of CO2/ air mixture with a rotation speed of 100 rpm. Exponentially growing<br><br>
cells in 3 L spinner flask were collected and inoculated into 7.5 L bioreactor with a<br><br>
working volume of 5 L. Dextran sulfate (500 kDa) was added at the concentration of<br><br>
200 mg/L in the serum free medium in the bioreactor. From the fourth day after<br><br>
inoculation, the culture medium was collected every second day for 20 days. Cell<br><br>
viability was maintained above 92.7% during culture perfusion, and factor VIII <br><br>
fragment was detected less than 5% judged by densitometric analysis of each band<br><br>
in Western blot during fermentation process. Exemplary Western blots of culture<br><br>
media collected on day 6, day 12 and day 18 were included in figure 4.<br><br>
Example 5<br><br>
Purification of 12GdBN from culture media by immuno affinity chromatography<br><br>
Due to the highly negative characteristic of dextran sulfate, ionic exchange<br><br>
chromatography cannot be applied to purify secreted factor VIII in culture media<br><br>
supplemented with dextran sulfate. Therefore, culture media produced in example 4<br><br>
were concentrated by the tangential flow ultrafiltration and subjected to an<br><br>
immunoaffinity column pre-equilibrated with equilibration buffer (20 mM of Tris-<br><br>
HCl [pH 7.0], 400 mM NaCl, 5 mM CaCl2, 3 mM EDTA). Immunoaffinity column<br><br>
was prepared by coupling monoclonal anti-factor VIII that recognizes A2 region of<br><br>
factor VIII heavy chain, to CNBr-activated sepharose resins. Factor Vlll-bound<br><br>
immunoaffinity column was washed with 2.5 bed volume of equilibration buffer and<br><br>
2.5 bed volume of washing buffer(20 mM of Tris-HCl [pH 7.0], 400 mM NaCl, 5 mM<br><br>
CaCl2, 3 mM EDTA, 10% ethylene glycol). Elution was performed in a stepwise<br><br>
gradient elution with elution buffers containing ethylene glycol at the concentration<br><br>
ranging from 40-60%. Nine of 12 elution fractions (elution fraction number 1 to 9<br><br>
corresponded to El to E9 in figure 5) were sampled and subjected to 7.5% of SDS- <br><br>
PAGE and stained with Coomassie brilliant blue R 250 dye. Only one-step<br><br>
purification of the culture medium gave more than 95% of highly pure single-chain<br><br>
factor VIII as illustrated in figure 5. <br><br>
We Claim:<br><br>
1. A method for producing recombinant Factor VIII from mammalian host cells<br><br>
transformed with the expression DNA vector containing cDNA coding for FVIII or<br><br>
FVIII derivatives in a culture medium and purifying said factor VIII using factor VIII<br><br>
specific affinity molecules linked to the solid support, comprising<br><br>
(a) culturing said mammalian host cells in a culture medium, which is<br><br>
supplemented with dextran sulfate;<br><br>
(b) concentrating said culture medium containing factor VIII through<br><br>
ultrafiltration; and<br><br>
(c) purifying said factor VIII from the concentrated culture medium by<br><br>
immunological method.<br><br>
2. The method according to claim 1, wherein average molecular weight of said<br><br>
dextran sulfate is 20 to 5,000 kDa.<br><br>
3. The method according to claim 1, wherein the amount of said sulfated<br><br>
polysaccharide in said culture medium is 10 mg/L to 2 g/L.<br><br>
4. The method according to claim 1, wherein said culture medium is a medium free <br><br>
of an animal protein.<br><br>
5. The method according to a claim 1, wherein said mammalian host cells are CHO,<br><br>
BHK, and COS cells.<br><br>
6. The method according to claim 1, wherein said immunological method is an<br><br>
immunoprecipitation or an immunoaffinity chromatography.<br><br>
7. The method according to claim 6, wherein said chromatography comprising,<br><br>
(a) a column packed with anti-factor VIII specific antibody coupled solid<br><br>
support including agarose and sepharose, and<br><br>
(b) an elution buffer containing buffering agents, salts, calcium chloride,<br><br>
detergent and ethylene glycol for Factor VIII molecules bound to said<br><br>
antibody coupled solid support.</td>
			</tr>
		</table>	
		<br>
		<h3>Documents:</h3>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTU4MC1NVU1OUC0yMDA5LUFCU1RSQUNUKDI0LTgtMjAwOSkucGRm" target="_blank" style="word-wrap:break-word;">1580-MUMNP-2009-ABSTRACT(24-8-2009).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTU4MC1NVU1OUC0yMDA5LUNMQUlNUygyNC04LTIwMDkpLnBkZg==" target="_blank" style="word-wrap:break-word;">1580-MUMNP-2009-CLAIMS(24-8-2009).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTU4MC1NVU1OUC0yMDA5LUNMQUlNUyhBTUVOREVEKS0oMjAtOC0yMDE0KS5wZGY=" target="_blank" style="word-wrap:break-word;">1580-MUMNP-2009-CLAIMS(AMENDED)-(20-8-2014).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTU4MC1NVU1OUC0yMDA5LUNMQUlNUyhBTUVOREVEKS0oMjctMi0yMDEzKS5wZGY=" target="_blank" style="word-wrap:break-word;">1580-MUMNP-2009-CLAIMS(AMENDED)-(27-2-2013).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTU4MC1NVU1OUC0yMDA5LUNMQUlNUyhNQVJLRUQgQ09QWSktKDIwLTgtMjAxNCkucGRm" target="_blank" style="word-wrap:break-word;">1580-MUMNP-2009-CLAIMS(MARKED COPY)-(20-8-2014).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTU4MC1NVU1OUC0yMDA5LUNMQUlNUyhNQVJLRUQgQ09QWSktKDI3LTItMjAxMykucGRm" target="_blank" style="word-wrap:break-word;">1580-MUMNP-2009-CLAIMS(MARKED COPY)-(27-2-2013).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTU4MC1NVU1OUC0yMDA5LUNPUlJFU1BPTkRFTkNFKDI0LTEwLTIwMTMpLnBkZg==" target="_blank" style="word-wrap:break-word;">1580-MUMNP-2009-CORRESPONDENCE(24-10-2013).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTU4MC1NVU1OUC0yMDA5LUNPUlJFU1BPTkRFTkNFKDI3LTEwLTIwMTApLnBkZg==" target="_blank" style="word-wrap:break-word;">1580-MUMNP-2009-CORRESPONDENCE(27-10-2010).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTU4MC1NVU1OUC0yMDA5LUNPUlJFU1BPTkRFTkNFKDI3LTgtMjAwOSkucGRm" target="_blank" style="word-wrap:break-word;">1580-MUMNP-2009-CORRESPONDENCE(27-8-2009).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTU4MC1NVU1OUC0yMDA5LUNPUlJFU1BPTkRFTkNFKDMwLTctMjAxMikucGRm" target="_blank" style="word-wrap:break-word;">1580-MUMNP-2009-CORRESPONDENCE(30-7-2012).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTU4MC1NVU1OUC0yMDA5LUNPUlJFU1BPTkRFTkNFKDYtMTEtMjAwOSkucGRm" target="_blank" style="word-wrap:break-word;">1580-MUMNP-2009-CORRESPONDENCE(6-11-2009).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTU4MC1NVU1OUC0yMDA5LUNPUlJFU1BPTkRFTkNFKDktMi0yMDEwKS5wZGY=" target="_blank" style="word-wrap:break-word;">1580-MUMNP-2009-CORRESPONDENCE(9-2-2010).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTU4MC1NVU1OUC0yMDA5LURFU0NSSVBUSU9OKENPTVBMRVRFKS0oMjQtOC0yMDA5KS5wZGY=" target="_blank" style="word-wrap:break-word;">1580-MUMNP-2009-DESCRIPTION(COMPLETE)-(24-8-2009).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTU4MC1NVU1OUC0yMDA5LURSQVdJTkcoMjQtOC0yMDA5KS5wZGY=" target="_blank" style="word-wrap:break-word;">1580-MUMNP-2009-DRAWING(24-8-2009).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTU4MC1NVU1OUC0yMDA5LURSQVdJTkcoMjctMi0yMDEzKS5wZGY=" target="_blank" style="word-wrap:break-word;">1580-MUMNP-2009-DRAWING(27-2-2013).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTU4MC1NVU1OUC0yMDA5LUZPUk0gMSgyNC04LTIwMDkpLnBkZg==" target="_blank" style="word-wrap:break-word;">1580-MUMNP-2009-FORM 1(24-8-2009).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTU4MC1NVU1OUC0yMDA5LUZPUk0gMSgyNy0yLTIwMTMpLnBkZg==" target="_blank" style="word-wrap:break-word;">1580-MUMNP-2009-FORM 1(27-2-2013).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTU4MC1NVU1OUC0yMDA5LUZPUk0gMSgzMC03LTIwMTIpLnBkZg==" target="_blank" style="word-wrap:break-word;">1580-MUMNP-2009-FORM 1(30-7-2012).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTU4MC1NVU1OUC0yMDA5LUZPUk0gMTMoMzAtNy0yMDEyKS5wZGY=" target="_blank" style="word-wrap:break-word;">1580-MUMNP-2009-FORM 13(30-7-2012).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTU4MC1NVU1OUC0yMDA5LUZPUk0gMTgoMjctMTAtMjAxMCkucGRm" target="_blank" style="word-wrap:break-word;">1580-MUMNP-2009-FORM 18(27-10-2010).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTU4MC1NVU1OUC0yMDA5LUZPUk0gMihDT01QTEVURSktKDI0LTgtMjAwOSkucGRm" target="_blank" style="word-wrap:break-word;">1580-MUMNP-2009-FORM 2(COMPLETE)-(24-8-2009).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTU4MC1NVU1OUC0yMDA5LUZPUk0gMihUSVRMRSBQQUdFKS0oMjQtOC0yMDA5KS5wZGY=" target="_blank" style="word-wrap:break-word;">1580-MUMNP-2009-FORM 2(TITLE PAGE)-(24-8-2009).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTU4MC1NVU1OUC0yMDA5LUZPUk0gMjYoMjQtOC0yMDA5KS5wZGY=" target="_blank" style="word-wrap:break-word;">1580-MUMNP-2009-FORM 26(24-8-2009).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTU4MC1NVU1OUC0yMDA5LUZPUk0gMygyNC0xMC0yMDEzKS5wZGY=" target="_blank" style="word-wrap:break-word;">1580-MUMNP-2009-FORM 3(24-10-2013).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTU4MC1NVU1OUC0yMDA5LUZPUk0gMygyNC04LTIwMDkpLnBkZg==" target="_blank" style="word-wrap:break-word;">1580-MUMNP-2009-FORM 3(24-8-2009).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTU4MC1NVU1OUC0yMDA5LUZPUk0gMygyNy0yLTIwMTMpLnBkZg==" target="_blank" style="word-wrap:break-word;">1580-MUMNP-2009-FORM 3(27-2-2013).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTU4MC1NVU1OUC0yMDA5LUZPUk0gMyg5LTItMjAxMCkucGRm" target="_blank" style="word-wrap:break-word;">1580-MUMNP-2009-FORM 3(9-2-2010).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTU4MC1NVU1OUC0yMDA5LUZPUk0gNSgyNC04LTIwMDkpLnBkZg==" target="_blank" style="word-wrap:break-word;">1580-MUMNP-2009-FORM 5(24-8-2009).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTU4MC1NVU1OUC0yMDA5LU9USEVSIERPQ1VNRU5UKDIwLTgtMjAxNCkucGRm" target="_blank" style="word-wrap:break-word;">1580-MUMNP-2009-OTHER DOCUMENT(20-8-2014).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTU4MC1NVU1OUC0yMDA5LU9USEVSIERPQ1VNRU5UKDI3LTItMjAxMykucGRm" target="_blank" style="word-wrap:break-word;">1580-MUMNP-2009-OTHER DOCUMENT(27-2-2013).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTU4MC1NVU1OUC0yMDA5LVBDVCBJQiAzMjYoNi0xMS0yMDA5KS5wZGY=" target="_blank" style="word-wrap:break-word;">1580-MUMNP-2009-PCT IB 326(6-11-2009).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTU4MC1NVU1OUC0yMDA5LVBDVCBJU0EgMjM3KDYtMTEtMjAwOSkucGRm" target="_blank" style="word-wrap:break-word;">1580-MUMNP-2009-PCT ISA 237(6-11-2009).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTU4MC1NVU1OUC0yMDA5LVJFUExZIFRPIEVYQU1JTkFUSU9OIFJFUE9SVCgyNy0yLTIwMTMpLnBkZg==" target="_blank" style="word-wrap:break-word;">1580-MUMNP-2009-REPLY TO EXAMINATION REPORT(27-2-2013).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTU4MC1NVU1OUC0yMDA5LVJFUExZIFRPIEhFQVJJTkcoMjAtOC0yMDE0KS5wZGY=" target="_blank" style="word-wrap:break-word;">1580-MUMNP-2009-REPLY TO HEARING(20-8-2014).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=MTU4MC1NVU1OUC0yMDA5LVdPIElOVEVSTkFUSU9OQUwgUFVCTElDQVRJT04gUkVQT1JUKDI0LTgtMjAwOSkucGRm" target="_blank" style="word-wrap:break-word;">1580-MUMNP-2009-WO INTERNATIONAL PUBLICATION REPORT(24-8-2009).pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=YWJzdHJhY3QxLmpwZw==" target="_blank" style="word-wrap:break-word;">abstract1.jpg</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=RHJhd2luZ3MucGRm" target="_blank" style="word-wrap:break-word;">Drawings.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Rm9ybS0xLnBkZg==" target="_blank" style="word-wrap:break-word;">Form-1.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Rm9ybS0zLnBkZg==" target="_blank" style="word-wrap:break-word;">Form-3.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=Rm9ybS01LnBkZg==" target="_blank" style="word-wrap:break-word;">Form-5.pdf</a></p>
				<p><a href="http://ipindiaonline.gov.in/patentsearch/GrantedSearch/pdfviewer.aspx?AppNo=UGV0aXRpb24gZm9yIGZvcm0gMy5wZGY=" target="_blank" style="word-wrap:break-word;">Petition for form 3.pdf</a></p>
		<br>
		<div class="pull-left">
			<a href="263855-pegylated-insulin-lispro-compound.html">&laquo; Previous Patent</a>
		</div>
		<div class="pull-right">
			<a href="263857-health-food.html">Next Patent &raquo;</a>
		</div>			
	</div><!-- /span8 -->
	<div class="span4">
		<div class="well infobox">
			<table class="table table-condensed">
				<tr>
					<th>Patent Number</th>
					<td>263856</td>
				</tr>
				<tr>
					<th>Indian Patent Application Number</th>
					<td>1580/MUMNP/2009</td>
				</tr>
				<tr>
					<th>PG Journal Number</th>
					<td>48/2014</td>
				</tr>
				<tr>
					<th>Publication Date</th>
					<td>28-Nov-2014</td>
				</tr>
				<tr>
					<th>Grant Date</th>
					<td>25-Nov-2014</td>
				</tr>
				<tr>
					<th>Date of Filing</th>
					<td>24-Aug-2009</td>
				</tr>
				<tr>
					<th>Name of Patentee</th>
					<td>SK CHEMICALS CO.  LTD.</td>
				</tr>
				<tr>
					<th>Applicant Address</th>
					<td>600 JEONGJA 1(IL)-DONG JANGAN-GU SUWON-SI GYEONGGI-DO</td>
				</tr>
				<tr>
					<td colspan=2>
								<h5>Inventors:</h5>
								<table class="table">
									<tr>
										<th>#</th>
										<th>Inventor's Name</th>
										<th>Inventor's Address</th>
									</tr>

										<tr>
											<td>1</td>
											<td>SONG  IN-YOUNG</td>
											<td>107-1407 DOOSAN WE’VE APT. 1278 GURO 3(SAM) – DONG GURO-GU SEOUL 152-053</td>
										</tr>
										<tr>
											<td>2</td>
											<td>KIM  HUN-TAEK</td>
											<td>345-1201 HANSIN 25-CHA JAMWON-DONG SEOCHO-GU SEOUL 137-796</td>
										</tr>
										<tr>
											<td>3</td>
											<td>KIM  JONG-WAN</td>
											<td>101-505 1-DANJI JUNGANG HEIGHTS VILLE APT. JEONGNEUNG 2(I)-DONG SEOUNGBUKGU SEOUL 136-779</td>
										</tr>
										<tr>
											<td>4</td>
											<td>KIM  YONG-KOOK</td>
											<td>2113-901 BAEKHYEON MAEUL DONGIL HIVILL JUNG-DONG GIHEUNG-GU YOUNGIN-SI GYEONGGI-DO 446-753</td>
										</tr>
										<tr>
											<td>5</td>
											<td>RYU  JONG II</td>
											<td>105-901 PRUGIO APT. DEOKGYE-DONG YANGJU-SI GYEONGGI-DO 482-719</td>
										</tr>
										<tr>
											<td>6</td>
											<td>KIM  DAE-KEE</td>
											<td>4-705 SHINDONG-A APT. 481 BON-DONG DONGJAK-GU SEOUL 156-768</td>
										</tr>
								</table>
					</td>
				</tr>
				<tr>
					<th>PCT International Classification Number</th>
					<td>C12P21/00</td>
				</tr>
				<tr>
					<th>PCT International Application Number</th>
					<td>PCT/KR2007/000947</td>
				</tr>
				<tr>
					<th>PCT International Filing date</th>
					<td>2007-02-23</td>
				</tr>
				<tr>
					<td colspan=2>
						<h5>PCT Conventions:</h5>
						<table class="table">
							<tr>
								<th>#</th>
								<th>PCT Application Number</th>
								<th>Date of Convention</th>
								<th>Priority Country</th>
							</tr>

								<tr>
									<td>1</td>
									<td></td>
									<td></td>
								    <td>NA</td>
								</tr>

						</table>
					</td>
				</tr>
			</table>
		</div><!-- /well -->
	</div><!-- /span4 -->
</div><!-- /row-fluid -->

        </div>

      </div><!--/row-->

      <footer class="footer">

        <style>
        .allindianpatents-footer { width: 320px; height: 50px; }
        @media(min-width: 500px) { .allindianpatents-footer { width: 468px; height: 60px; } }
        @media(min-width: 800px) { .allindianpatents-footer { width: 728px; height: 90px; } }
        </style>
        <center>
        </center>

        <p>&copy; All Indian Patents, 2013-2021.</p>
        <p>Patent data available in the public domain from Indian Patents Office, Department of Industrial Policy and Promotions, Ministry of Commerce and Industry, Government of India.</p>
      </footer>

    </div> <!-- /container -->

    <!-- Javascripts
    ================================================== -->
    <!-- Placed at the end of the document so the pages load faster -->
    <script src="../assets/application-95f297ff0d8d2015987f04b30593c800.js" type="text/javascript"></script>

    <!-- Start of StatCounter Code for Default Guide -->
    <script type="text/javascript">
    var sc_project=8902313; 
    var sc_invisible=1; 
    var sc_security="3c1f8147"; 
    var scJsHost = (("https:" == document.location.protocol) ?
    "https://secure." : "http://www.");
    document.write("<sc"+"ript type='text/javascript' src='" +
    scJsHost+
    "statcounter.com/counter/counter.js'></"+"script>");
    </script>
    <noscript><div class="statcounter"><a title="web stats"
    href="http://statcounter.com/free-web-stats/"
    target="_blank"><img class="statcounter"
    src="http://c.statcounter.com/8902313/0/3c1f8147/1/"
    alt="web stats"></a></div></noscript>
    <!-- End of StatCounter Code for Default Guide -->

    <script>
      (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
      (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
      m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
      })(window,document,'script','http://www.google-analytics.com/analytics.js','ga');

      ga('create', 'UA-244143-31', 'allindianpatents.com');
      ga('send', 'pageview');

    </script>

  </body>

<!-- Mirrored from www.allindianpatents.com/patents/263856-process-for-producing-and-purifying-factor-viii-and-its-derivatives by HTTrack Website Copier/3.x [XR&CO'2014], Thu, 04 Apr 2024 22:41:36 GMT -->
</html>
